Introduction
Chronic lymphocytic leukemia (CLL) cells develop in the bone marrow (BM) and lymph node (LN) 'proliferative' compartments in crucial support by cellular and humoral milieu components [1] . of a putative human innate B cell population, similar to mouse B1 cells [2, 3] , albeit the cellof-origin is still debated [4, 5] . For a better understanding of the role of antigens and growth factors in the microenvironment, multiple experimental models have been reported. However, none of these animal or co-culture systems completely mirrors the in vivo scenario [6] .
Nevertheless, the importance of pro-survival influences from stromal-cell derived thioredoxin 1 (Trx1) [7] [8] [9] [10] , stem-cell factors produced by nurse-like cells [11] , CD40L-transfected feeder cells [3] , and macrophage feeder [12] have been highlighted. Without such support, CLL cells do not proliferate in vitro and quickly die by growth factor deprivation. The analytical options of these co-cultures are limited even though the CLL cells can be activated and stimulated for several divisions [8] .
Cultures of CLL-derived lymphoblastoid cell lines (CLL-LCLs) continue to produce mAbs and express genomic aberrations such as del(13q14), trisomy 12, del(11q), del(17p) identical to the in vivo patient leukemic clone [3] . One functionally crucial exception would be that LCLs are EBV-transformed in contrast to the majority of primary CLL cells. Resting peripheral blood (PB) B cells from healthy donors are readily transformed by EBV into LCLs with retained traits, including Ab production [13] [14] [15] , whereas CLL B-cells are generally resistant to EBV-induced transformation. While the CLL cells carry the virus receptor CD21 and can be infected, these cells usually do not transform to cell lines, due to a very restricted expression of the EBV-encoded genes lacking LMP1 (latency IIb program) [16] .
Consequently, upon exposure of a CLL sample to EBV in culture, it is the normal B cell fraction that is more easily transformed [17, 18] .
A few rare CLL-LCLs have been established from such in vivo infected clones, however, most cell lines that do exist were derived from in vitro EBV-infections, and both types of cell lines exhibit full latency III program. Considering the higher accessibility to EBV transformation of normal B cells over CLL B cells in such a mixed culture, the few long-term CLL-LCLs that do exist have been questioned as to their correct neoplastic origin.
In this study, we present a detailed genomic and phenotypic analysis of a panel of such CLL cell lines [17, [19] [20] [21] [22] [23] , including those claimed to be normal B cell derived LCLs from the same donors [17] . The main purpose of this study was to collect evidence of unique clonal 4 identity and authenticity of the cell lines. We have analyzed the most relevant molecular features such as Ab-reactivities, genetic aberrations, and certain activation markers (i.e. CD38, ZAP0, TCL1, CLLU1), with particular emphasis on neoplastic-to-normal B cell compartment. The LCLs represent models for activated CLL cells useful for analyses of DNA aberrations in leukemic cells and they are a renewable source of natural antibodies in studies of antigen structures.
5

Materials and methods
CLL cell lines
CLL cell lines (Table 1) were cultured in RPMI 140 medium supplemented with 10% FCS. 100 U/ml penicillin and 100 g/ml streptomycin.
Immunoglobulin gene sequencing
DNA was extracted according to standard procedures using proteinase K. IGHV, IGKV and IGLV subgroup-specific PCR amplification and nucleotide sequencing was performed as published [24] . The DYEnamic ET Dye Terminator Kit (Amersham Biosciences, Piscataway, NJ) was used for sequence reactions to be analysed by an automated DNA sequencer (MegaBACE 1000 DNA Analysis System, Amersham Bioscience, Sunnyvale, CA).
Sequences were submitted to the IMGT/V-QUEST database. Germline identity of <98% to the corresponding IGHV, IGKV and IGLV germline genes was defined as mutated. All HCDR3 sequences were compared with published sequences for stereotyped subsets [25] .
Real-time quantitative PCR (RQ-PCR)
RQ-PCR for FMOD and CLLU1 was performed according to previously published procedures [26, 27] . For TCL1 we used RT-PCR (forward primer: GGAGAAGTTCGTGTATTTGG, reverse: CGCCGTCAATCTTGATG). RT-PCR data represent β-actin normalized levels. DoHH2 B cells and their stably TCL1-transfected sublines DoHH2-TCL1 served as controls [28] .
FISH analysis
Cell lines were analyzed for genomic aberrations using a CLL FISH probe panel including probes for 11q22.3 (ATM), 17p13.1 (p53), 12cen (CEP12), 13q14.3 (D13S319) and 13q34 (VYSIS, Downers Grove, IL, USA). Fluorescence signals were enumerated in at least 200 interphase cells. The cut-off for positive values was set at >10%.
High resolution short tandem repeat (STR) analysis
DNA quantitative fluorescence PCR (QF-PCR) was performed in order to determine whether the CLL clone and its normal LCL counterpart originated from the same patient. Seventeen polymorphic microsatellite markers on chromosome 13, 18, 21, X and Y were amplified by PCR, using a ChromaQuant TM kit (CyberGene, Stockholm, Sweden) including fluorochrome-6 labelled primers, according to the manufacturer's instructions. The PCR fragments were analysed by capillary electrophoresis on a MegaBACE 500.
Protein expression/secretion analysis CD5, CD19, CD20, CD23, as well as IgM, Ig- and light chains were analyzed by flow cytometry as previously described [3] . IgG-production was analyzed by ELISA in IgMnegative cell lines. CD38 (HB-7, Becton Dickinson, Heidelberg, Germany) and TCL1 expression (clone 1-21 as PE-and APC-conjugates) were assessed by flow cytometry in 3 independent measurements for most cultures with isotype-controlled mean fluorescence intensity (MFI) reported to determine relative expression levels and with indicated percentage of positive cells (cut-off's 30%). ZAP70 expression was assessed using a customized flow cytometry protocol [29] . TCL1 and ZAP70 levels (Ab #D1C10E, Cell Signalling Technology Inc., Beverly, MA) were confirmed in all cases by Western blot (WB) with categorizations for TCL1 as published) [30] . Jurkat E6-1 cells and normal PB T cells represented positive controls for the WB and flow-cytometric analysis of ZAP70.
ELISA for autoantigens
Chemoluminescent-based ELISAs were used for analysis of Ab reactivities previously identified in tissue-arrays and protein-arrays [24] . Vimentin, oxidized LDL (oxLDL), proline-rich acidic protein-1, or cofilin-1 were coated onto MicroFluor2-plates, then cell linederived Abs were incubated overnight. Alkaline-phosphatase-anti-IgM was used as indicator Ab and plates were developed with LumiPhos530 substrate. Luminescence-intensity was recorded in a Wallac Victor2 luminometer. Competition-ELISA was used for validation. Abs were then preincubated with increasing concentrations of antigen for 18 h. Table I summarizes the panel of 17 CLL patient-derived cell lines, of which 10 were claimed to be of neoplastic (CLL-LCLs) and 7 of normal B cell origin (LCLs). The clinical information available for the CLL patients is presented together with the genetic and immunophenotypic characteristics of their corresponding established cell lines (Supplemental Table A-I) . If IGHV/IGKV/IGLV gene analysis, FISH cytogenetics, DNA genotyping and immunophenotype analysis were not included in the primary reports, we performed these tests on the cell lines, and also on patient blood samples received from biobanks. Here, we have followed the nomenclature suggested by Drexler [31] as follows: "Authentication" of derivation refers to conclusive proof of derivation from a particular patient; "verification" of neoplasticity refers to unequivocal proof of neoplastic origin of the cell line. The term 'verified' was used for molecular evidence supporting CLL neoplastic origin, but in contrast to the term 'authentic', the verified-only cell lines could not be assigned to a particular patient due to unavailability of blood sample.
Results
CLL and normal B cell lines from the same individuals
Initially six CLL/normal LCL pairs were available: I83-E95/I83-LCL, 232B4/232A4, Figure 1A ) with anti-oxLDL and vimentin specificity reacting with apoptotic Jurkat cells, whereas the normal LCL was IgM, of unknown specificity CD5-negative, normal karyotype, and identical DNA-fingerprint to patient (Table I, Supplemental   Table A , Supplemental Figure 1A ). The cell lines were previously established from 7-d cultures of EBV-infected CLL cells grown in the presence of Trx1, IL2 and SAC (heat inactivated S. aureus, Cowan I) followed by plating on irradiated human embryonal fibroblasts. [17] We conclude that I83-E95 represents the authentic malignant CLL clone and that I83-LCL was derived from the patient's normal B cells. is reminiscent of human B1 cells (Table I and Supplemental Table D (Table I and Supplemental Table E ), identical to the sequence of the patient clone as reported in the primary reference. It is not known whether the patient had concurrent CLL and PLL clones [33] and in case of concurrency, which one gave rise to MEC1 and MEC2 [32] . Figure 1F ), a true CLL origin in both CI and CII could be verified. In the primary reference, CI was described as a normal B cell [21] . Originally, the CII line contained two subpopulations, one with a 47,XX,+12 karyotype and a with a 47,XX, inv(11),+del(12) t(12;15) karyotype. The patient's normal tissue expressed both type-A and type-B of the isozyme glucose-6-phosphate dehydrogenase (G6PD), whereas the CII cell line expressed exclusively type-A G6PD, i.e. identical to the patient's blood CLL clone. CII and the patient's clone were IgM, n contrast, the CI cell line was karyotypically normal, expressed IgM, , and type-B G6PD, thus Karande et al. [21] assumed that CI was derived from non-leukemic normal B cells (Table 1 and Supplemental Table F PGA1/ PG/B95-8: PGA1 is another example of an in vivo EBV-transformed CLL clone growing out spontaneously in vitro without addition of B95-8 strain of EBV [22] . Its original 10 marker was a ring chromosome 15 that was also present in patient blood. This was eventually lost in cultures, whereas 13q-and +12 were maintained. CD5-expression was down-regulated ( Figure 2) . The PG/B95-8 represents a normal CD5-negative LCL with normal karyotype derived from the same donor (Supplemental Figure 1D) . We conclude that PGA1 is authentic, carrying trisomy 12, and an IGHJ-RFLP pattern identical to the patient's clone, and that PG/B95-8 sister cell line was derived from normal B cell of the PG patient.
AI-60/AII, AIII: The AI-60 was IgM,   with a 45X,-X karyotype and A-type G6PD identical to the blood CLL cells [34] . The AII and AIII were of leukemic origin on initial We found in this study a mutated IGHV1-18/IGHD5-12/IGHJ1 gene rearrangement with 82.8% germline identity ( Figure 1 ). FISH analysis showed extra copies of 11q (Table I) Table G ). We could not conclusively re-confirm/verify a neoplastic origin of the EHEB cell line in this study due to loss of CD5-expression, lack of CLL-markers, and inaccessibility to patient's blood cells. Figure 4A , B shows that FMOD and CLLU1 mRNA expression levels were low in comparison with a panel of patients' CLL cells (n=175) previously analyzed [35] .
Quantitative gene expression levels of FMOD and CLLU1
CD5 expression
CD5 is an obligatory marker for classification of CLL. It is also present on most, but not all, innate human B cells, resembling murine B1 B cells, and it is considered to be associated with 
CD38, ZAP70 and TCL1
Protein expression values of CD38, ZAP70, and the TCL1 proto-oncogene are summarized in Table II -. 232B4 and 232A4 were both CD38-negative, but showed ZAP70 and TCL1-expression, which tended to be higher in the 232B4 CLL line than in the normal 232A4 LCL (Table II, Figure 5B ). PGA1 (CLL-LCL) and PG/B95-8 (normal LCL) were both low in CD38 and TCL1 expression, although slightly increased levels were observed in PGA1 compared with PG/B95-8. ZAP70 was absent in both cell lines (Table II) . In these LCLs, the activation marker CD38 showed an expression gradient with a high degree of spread across one culture, while ZAP70 and TCL1 were more uniformly expressed. There was no obvious association of CD38, ZAP70, or TCL1 expression with each other or with IGHV mutation status.
Discussion
We here present detailed authenticity characterization of a collection of 17 CLL patientderived cell lines, of which 8 were found to be authentic neoplastic origin, 2 of verified CLL origin, and 5 derived from the patients' normal B-cells. We comprehensively catalogue the differences between leukemic LCLs and normal B-cell LCLs derived from the same CLL patients including analyses of gene and protein expression patterns of CLL-relevant molecules.
A substantial challenge in understanding CLL biology is to understand the role of antigen in the proliferative lymphoid milieu in contrast to peripheral blood (resting) compartment, where antigen is absent. Although animal models have contributed considerably to closing many knowledge gaps in CLL, these have certain limitations, such as cell subset access and fidelity issues [6] . Therefore, and in light of the relentless apoptosis induction occurring in primary CLL cultures, the generation of immortalized CLL cell lines has been highly desirable, as these represent important supplemental tools with benefits of high reproducibility and easy-access, in particular for mAb (IG gene/protein).
With the recent advent of co-culture systems for prolonged cultivation of CLL cells using macrophages [12] , CD40L-transfected fibroblasts [3] , or patient-derived stromal cells [7] , there has been an improvement in the frequency of obtained EBV-transformed CLL clones. For stable long-term Ab-production, fusion of the EBV-transformed CLL cells with the K6H6/B5 heteromyeloma (mouse NS-1-Ag4 myeloma × human nodular lymphoma cells) appears to be a very valuable tool [12] . For genetic studies, however, these hybrids suffer A key feature of the CLL clone is the IG structure/specificity, since it provides information on the function and differentiation of the CLL B cell progenitor. CLL B cells share several properties with CD5 + B1 cells described in mice [2] , but also with mature CD5 + 13 B cells [5] . CLL cells have a highly restricted "stereotyped" BCR repertoire in ~30% of cases [25, 36] . We found that 6 of the 8 CLL-LCLs produced 'natural' Abs against oxidationspecific self-antigens and the mAb production was maintained in the cell lines over long time.
The natural Ab repertoire has previously only been described for murine CD5 + B1 cells [24, 37] . Overall, with respect to BCR 'anatomy' (ie. CDR3 sequence, IGHV gene segment usage, surface IgM-expression) and Ab-secretion, but also to a large degree based on immunophenotype, our set of cell lines represents key features of primary human CLL.
The expression levels of CD38, ZAP70, TCL1, FMOD, CLLU1 were generally lower in the cell lines compared with levels in CLL patients' blood cells, but interestingly ZAP70 and TCL1 tended to be expressed at slightly higher levels in the CLL cell lines than in their samepatient LCL sister cell lines. No conclusive answer can be provided as to why TCL1 levels found in these CLL cell lines tended to be lower than in fresh primary CLL samples (not shown [30, 38] . It is also known that EBV-gene products regulate TCL1 in a latency-program dependent fashion [39, 40] . Furthermore, we found that FMOD expression did not differ in CLL-LCLs vs. LCLs from normal B-cells, although the expression was low as compared with primary CLL cells ( Figure 4A, B) . Interestingly, EBV specifically interferes with and mimics micro-milieu fed activation pathways that are most central in CLL, such as BCR and CD40L
cascades. Küppers and co-workers described EBV overriding the gene expression patterns of B-cell differentiation [41] . Overall, influences by EBV and the altered culture environment likely affect ZAP70, CD38, CLLU1, FMOD, and TCL1 expression through pathway and regulatory interferences.
Although EBV-transformed LCLs have provided a conveniently accessible and renewable resource for functional studies of gene expression and epigenetic regulation [42] , their utility of LCLs as a surrogate model for primary tissues -B cells in particular, has been questioned due to the effect of EBV-transformation. Çalişkan et al. [42] . found that 6464 genes were differentially expressed between primary B cells and LCLs, but that most of the expression differences were of small magnitude with only 33 genes differentially expressed with a fold change of >1.5. Based on their detailed global expression arrays and methylation profiling, they conclude that LCLs may be faithful models for expression quantitative trait loci (eQTL), and suggest that inference of the genetic architecture that underlies regulator variation in LCLs can typically be generalized to primary B cells, whereas inference based on functional studies in LCLs may be more limited to the cell lines In summary, we here explored the authenticity of malignant CLL cell lines based on genetic and phenotypic analyses, and we showed the individual CLL-representative nature of 14 these systems including innate CD5 + B cell features. Inferences based on factors responsible for survival and proliferation of CLL cells cannot be made due to EBV imprinting in these cell lines. We regard this collection of authentic CLL and sister LCLs as valuable tools for studies on antibody-specificities, and genetic (DNA) aberrations during the leukemogenesis.
As any model, these LCLs have to be analyzed ideally in conjunction with primary tissues. Fig. 1 ). I83-E95 CLL and the I83-LCL had identical STR-fragment profiles, proving their derivation from the same individual (Supplemental Fig. 1 Table 1 ). The Wa-osel cell line had a tetraploid karyotype (Table 1) . DNA/STR-fingerprinting showed that WaC3CD5 + and Wa-osel were derived from the same person (Supplemental Fig. 1 ). WaC3CD5 + was CD5 + and Wa-osel CD5 - (Fig. 3) . Both lines lack CD38, ZAP70 and TCL1 (Table 2) , however, a TCL1 dim subpopulation was detected in flow cytometry in Wa-osel. We conclude that WaC3CD5 + and Wa-osel are authentic CLL neoplastic clones. The WaC3CD5 + line is biclonal due to either a lack of allelic exclusion as reported previously, [2, 3] or more likely, presence of two separate monoclonal CLL populations, [4] since the rearranged IGHV genes were of different size. The Wa-osel cell line is monoclonal. (Fig. 1) . The sister cell line 232A4 had an unrelated and mutated
Supplemental
IGHV1-46/IGHD5-5/IGHJ6
gene rearrangement, and showed a normal karyotype as described by primary reference. STR-analysis revealed identical origin of 232B4 and 232A4 cell lines (Fig. 2) (Fig. 3) . Both lines were CD38-negative, but showed ZAP70 and TCL1 expression, which tended to be higher in the 232B4 CLL line than in the 232A4 LCL (Table 2) . We conclude that the 232B4 cell line is authentic with one of the CLL patient leukemic clones and confirm that the 232A4 cell line was of normal LCL origin. (Fig. 1) . The IGHV and IGLV rearrangement showed 100% identity to germline genes. FISH analysis revealed a biallelic del(13q) ( Table 1 (Fig. 3) . The cells were CD38 and ZAP70 positive and showed low-level TCL1 expression (Table 2) . We conclude that HG3 CLL line is of authentic CLL origin. Comments: MEC1 and MEC2 cell lines were previously established by Caligaris-Cappio and co-workers from a 58-year-old male diagnosed with CLL in prolymphocytoid transformation. [1] The cell lines were established by spontaneous outgrowth at two subsequent occasions. They showed identical mutated IGHV4-59 rearrangement with the patient's leukemic clone. CD5 expression was lost in both cell lines upon continued cell culturing. The karyotypes of the cell lines were abnormal with multiple aberrations, and cytogenetic studies on the parental cells were unsuccessful. We reconfirmed that both MEC1 and MEC2 cell lines had identical IGHV4-59/IGHD2-21/IGHJ4 gene rearrangement as described in the primary reference. 42 MEC1 cells lacked CD5 and only a dim expression was noted for CD38 and TCL1, while ZAP70 was completely absent (Table 2) . We conclude that authenticity for both cell lines was certified (Fig. 1) .
Supplemental
Supplemental Table F
Comments:
CI and CII. Originally, the CII cell line contained two subpopulations, one with a 47,XX,+12 karyotype and a second population with a 47,XX, inv(11),+del(12) t(12;15) karyotype. The patient's normal tissue (skin and red blood cells) expressed both type-A and type-B of glucose-6-phosphate dehydrogenase (G6PD), whereas the CII cell line expressed exclusively type-A G6PD pattern, which was identical to the patient's peripheral blood CLL clone. CII and the patient's clone were "monoclonal" Ig producers with an IgM, l phenotype. The CI cell line was karyotypically normal, expressed IgM, k, and type-B G6PD, thus Karande et al. assumed that CI were derived from non-leukemic normal B cells. [8] Based on G6PD, surface IgM, k  or l, chromosome markers, Fc-receptors and malic enzyme, the authors concluded that CII was of leukemic and CI of normal B cell origin. In our extended molecular characterization, we found that the CII cell line had unmutated IGHV1-69/IGHD3-10/IGHJ6 and IGLV1-4/IGLJ3 gene rearrangements (Fig. 1) . The HCDR3 sequence of this cell line showed homology with the 'stereotyped' CLL subset-5, described by Murray et al. [6] FISH analysis of the cell line revealed a trisomy/tetrasomy 12, in line with the primary report ( Table 1 ). The CI cell line had identical IGHV gene rearrangements with the CII cell line, but noteworthy, the FISH results were not identical. The CII and CI cell lines both displayed a CD5 (Fig. 3) . CII cells showed low CD38 density in the majority of cells and were characterized by high ZAP70 and TCL1 levels ( Table 2 ). In view of the presence of a stereotyped HCDR3, which constitutes an almost unique phenomenon for CLL (scarcely described in other B cell neoplasias), a subset membership is thus an important piece of evidence for true CLL origin. Hence, the HCDR3 homology with subset-5 underscores an authentic CLL origin of the CII cell line. The trisomy/tetrasomy 12 revealed by FISH is consistent with primary reference, with trisomy 12 being one of the most common recurrent aberrations observed in patients with CLL, [11] although it is not specific for this disease. IG gene sequence alignment with patient in vivo CLL clones was not possible, since DNA from original patient's blood samples was not available. The CI (normal) cell line was collected from different laboratories (e.g. Uppsala University, Karolinska Institute, and Linköping University). All CI cells showed IGHV1-69/subset-5 rearrangements, identical with the CII cell line. These data together with the CD5 + /CD19 + phenotype strongly indicates that this cell line early in the establishment history of the cell line was cross-contaminated with the neoplastic CII clone, alternatively, CI, which originally was described as normal, was overgrown by the neoplastic clone (based on the assumption that the original culture contained a few neoplastic cells along with normal B cells). We conclude that expression of CLL signature markers (identical to the in vivo clone), e.g. trisomy 12 (also in the in vivo clone), and a BCR belonging to the stereotyped subset-5, are strong indicators of an authentic CLL origin of both CI and CII.
Supplemental Table G
Comments: PGA1 and PG/B95-8. cell lines were established from a male CLL patient. [12, 13] + and CD45 + phenotype with a different IGH rearrangement as compared with the patient's CLL clone. The authors concluded that their data provided incontrovertible evidence that the directly outgrowing cell line PGA1 represented the leukemia cell in vivo. In this study we found that the PGA1 cell line showed a mutated IGHV4-39/IGHD4-17/IGHJ5 gene rearrangement with 91.8 % identity to germline (Fig.1) . FISH analysis showed trisomy 12 and del(13q) ( Table 1) . STR-analysis revealed identity between PGA1 and its sister PG/B95-8 LCL cell line (Supplemental Fig. 1 TCL1 expression. However, for both markers a tendency of slightly higher levels in the PGA1 CLL line than in the PG/B95-8 normal LCL cells was noted. ZAP70 was absent in both lines ( [12, 13] and that PG/B95-8 sister cell line represents a normal LCL B cell line from the PG patient.
Supplemental Table H
Comments: EHEB cell line was established from a 69-year-old female diagnosed with CLL in Rai stage II. [14] It showed identical IGH and IGL rearrangements with the patient's in vivo CLL cells, as shown by Southern blot analysis using restriction enzymes BglII, PstI, XbaI, SacI, BamHI and EcoRI with an IGHJ probe, Cκ probe and Cλ probe. It was karyotypically normal after one year in culture (originally the authors found a chromosome 11q aberration) and had a CD5 + , CD19 + , μ low , cytoplasmic κ + phenotype. Based on the identical gene rearrangements in the patient's blood and EHEB cell line, the authors concluded that the cell line was derived from the neoplastic clone. We found that the EHEB CLL cell line had a mutated IGHV1-18/IGHD5-12/IGHJ1 gene rearrangement with 82.8% identity to germline (Fig. 1) . FISH analysis showed extra copies of 11q (Table 1) Fig. 3 and Supplemental Table G) . We could not conclusively re-confirm/verify a neoplastic origin of the EHEB cell line in this study due to loss of CD5 expression, lack of CLL markers, and inaccessibility to patient's blood cells. Table I Comments. AI-60, AII, and AIII cell lines were established from a 54-year-old female CLL patient. [10] The AI-60 cell line had monospecific kappa- light chain expression, a 45,X,-X karyotype and showed only A-type G6PD, which was identical to the neoplastic blood cell expression (IgM, kappa, G6PD-A;45,X-X Fig,1) . AII and AIII were tested CD5-negative. AII showed strong CD38 and TCL1 Other markers Initially A-type G6PD, but eventually B-type G6PD only expression, while AIII was scored CD38-negative and with TCL1-positive protein levels lower than in AII (Table 2 ). Both lines were assigned a weak-positive ZAP70 score. We conclude that these three CLL cell lines established in 1979 have been used extensively for many years as a CLL leukemic prototype (AI-60) and normal sister cell lines (AII and AIII). Collectively these markers provided evidence that the EBV transformed cells were derived from the neoplastic clone. In the present study, we lacked patient's blood cells. Thus, we could not with certainty verify a neoplastic origin and due to retarded growth of AI-60, we could not perform further immunophenotyping and karyotyping.
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